Secondary prevention of coronary heart disease in Moscow-population patients with myocardial infarction
Abstract
Aim. To assess the implementation of international guidelines on coronary heart disease (CHD) treatment and secondary prevention into Russian clinical practice, by examining Moscow- population patients with myocardial infarction (MI).
Material and methods. Five thousand out-patient medical cards of the individuals, who attended the Moscow City Cardiology Dispanser in 2001, were randomly selected. Among them, 623 patients had MI in anamnesis. According to medical documents data, the prevalence of CHD risk factors (RF), drug therapy administered, invasive CHD diagnostics and treatment, and CHD secondary prevention advice, were analyzed.
Results. Among Moscow physicians, inadequate awareness on CHD RF was observed. International guidelines were not followed: in particular, under-treatment with statins, antiplatelet agents, effective doses of antihypertensives, as well as over-treatment with first-generation calcium antagonists, were registered. Invasive CHD diagnostics and treatment were still used rarely, comparing to developed countries in Europe and worldwide.
Conclusion. In the area of CHD secondary prevention for MI patients, a huge gap between international guidelines and actual clinical practice was observed.
About the Authors
R. G. Oganov
State Research Center For Preventive Medicine, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
V. K. Lepakhin
Russian University of People’s Friendship, Moscow
Russian Federation
Russian Federation
S. B. Fitilev
Russian University of People’s Friendship, Moscow
Russian Federation
Russian Federation
A. M. Levin
Russian University of People’s Friendship, Moscow
Russian Federation
Russian Federation
I. I. Shkrebneva
Russian University of People’s Friendship, Moscow
Russian Federation
Russian Federation
Yu. Yu. Titarova
Russian University of People’s Friendship, Moscow
Russian Federation
Russian Federation
S. V. Gromakovsaya
Russian University of People’s Friendship, Moscow
Russian Federation
Russian Federation
References
1. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15(10): 1300-31.
2. Pyorala K, Wood D. Prevention of coronary heart disease in clinical practice: European recommendations of the Second Task Force of the European and other Societies on coronary prevention, revived and reinforced. Eur Heart J 1998; 19(10): 1413-5.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular prevention in clinical practice: recommendations of the Third Joint Task Force of the European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24(17): 1601-10.
4. AHA Medical/Scientific Statement. Consensus Panel statement. Preventing Heart Attack and Death in Patients With Coronary Disease. Circulation, 1995; 92: 2-4.
5. EUROASPIRE Study Group. EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18: 1569-82.
6. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
7. EUROASPIRE I and II Study Group. Critical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. The Lancet 2001; 357: 995-1001.
8. Mayer O, Simon J, Heidrich Jr, et al. Educational level and risk profile of cardiac patients in the EUROASPIRE II substudy. J Epidemiol Community Health 2004; 58(1): 47-52.
9. EUROASPIRE I and II Study Group. Blood pressure in insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003; 21(10): 1831-40.
10. EUROASPIRE Study Group. Potential for cholesterol lowering in secondary prevention of coronary heart disease in Europe: findings from EUROASPIRE study. Atherosclerosis 2000; 153(2): 505-17.
11. Bertoni AG, Bonds DE, Lovato J, et al. Sex disparities in Procedure Use for Acute Myocardial Infarction in the United States, 1995 to 2001. Am Heart J 2004; 147(6): 1054-60.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet 1994; 344: 1383-9.
13. Heart Disease and Stroke Statistics – 2004 Update. American Heart Association.
14. Sans S, Kesteloot H, Kromhout D, et al. The Burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18(8): 1231-48.
Review
For citations:
Oganov R.G., Lepakhin V.K., Fitilev S.B., Levin A.M., Shkrebneva I.I., Titarova Yu.Yu., Gromakovsaya S.V. Secondary prevention of coronary heart disease in Moscow-population patients with myocardial infarction. Cardiovascular Therapy and Prevention. 2005;4(3, ч.I):53-60. (In Russ.)
Views:
1442
Email this article 
